Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Outcomes in Patients with NSTE-ACS Undergoing PCI on a Novel Tissue Factor/factor VIIa Inhibitor (rNAPc2) with Full, Half-Dose or No Heparin in the ANTHEM-TIMI 32 Trial

Outcomes in Patients with NSTE-ACS Undergoing PCI on a Novel Tissue Factor/factor VIIa Inhibitor (rNAPc2) with Full, Half-Dose or No Heparin in the ANTHEM-TIMI 32 Trial. TCT. 2006.


© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.